Lytix gets FDA Phase III clearance for ruxotemitide
FDA cleared Phase III for ruxotemitide. Lytix says its cash position supports advancing the clinical pipeline.
Story updates
05:04:06 AM UTC
SquawkNews
LYTIX: FDA cleared pivotal Phase III trial design; R&D spending rose, equity strengthened
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.